MC
IMRX icon

Moors & Cabot’s Immuneering IMRX Stock Holding History

Moors & Cabot’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.7K Hold
10,000
– – ﹤0.01% 912
2025
Q4 		$65.8K Sell
10,000
-1,000
-9% -$6.42K ﹤0.01% 901
2025
Q3 		$77K Buy
+11,000
New +$57.1K ﹤0.01% 886

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Moors & Cabot's IMRX Position: Q1 2026 in Review

Moors & Cabot held its Immuneering (IMRX) position steady in Q1 2026 at 10,000 shares worth $52.7K. The position accounts for ﹤0.01% of the portfolio, ranked #912.

Moors & Cabot first reported a position in IMRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $77K in Q3 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Moors & Cabot held 10,000 shares of Immuneering worth $52.7K as of Q1 2026.
  • Moors & Cabot left its Immuneering share count unchanged in Q1 2026.
  • Immuneering made up ﹤0.01% of Moors & Cabot's portfolio in Q1 2026, its #912 holding.
  • Moors & Cabot first reported a position in Immuneering in Q3 2025 and has held it in 3 quarters since.
  • Moors & Cabot's Immuneering position peaked at $77K in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.